Erratum: Complement as a multifaceted modulator of kidney transplant injury (Journal of Clinical Investigation (2014) 124: 6 (2348-2354) DOI: 10.1172/JCI72273);Complement as a multifaceted modulator of kidney transplant injury

Journal of Clinical Investigation

Volumn 124, Issue 6, 2014, Pages 2348-2354

  Cravedi, Paolo ^a   Heeger, Peter S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; HLA ANTIBODY; INTERLEUKIN 21 RECEPTOR; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA;

ALLOIMMUNITY; APOPTOSIS; CELL DIFFERENTIATION; CELL EXPANSION; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; FIBROSING ALVEOLITIS; HUMAN; HYPERTENSION; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TRANSPLANT INJURY; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ALLOGRAFTS; ANIMALS; COMPLEMENT ACTIVATION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY; KIDNEY TRANSPLANTATION; MODELS, IMMUNOLOGICAL; REPERFUSION INJURY; T-LYMPHOCYTES;

EID: 84902205962     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI81182     Document Type: Erratum

References (93)

1. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant. 2011;11(6):1226-1235.
2. Tapiawala SN, et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol. 2010;21(1):153-161.
3. Khalkhali HR, Ghafari A, Hajizadeh E, Kazemnejad A. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction. Exp Clin Transplant. 2010;8(4):277-282.
4. El Ters M, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant. 2013;13(9):2334-2341.
5. Smith JD, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11(2):312-319.
6. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant. 2004;4(3):438-443.
7. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol. 2009;4(12):2029-2034.
8. Kaposztas Z, Gyurus E, Kahan BD. New-onset diabetes after renal transplantation: diagnosis, incidence, risk factors, impact on outcomes, and novel implications. Transplant Proc. 2011;43(5):1375-1394.
9. Luft FC. How calcineurin inhibitors cause hypertension. Nephrol Dial Transplant. 2012;27(2):473-475.
10. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344(14):1058-1066.
11. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785-797.
12. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984;160(5):1558-1578.
13. Peake PW, O'Grady S, Pussell BA, Charlesworth JA. C3a is made by proximal tubular HK-2 cells and activates them via the C3a receptor. Kidney Int. 1999;56(5):1729-1736.
14. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cellexpressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. Blood. 2008;112(5):1759-1766.
15. Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant. 2011;11(11):2279-2296.
16. Zhou W, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105(10):1363-1371.
17. Thurman JM, et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest. 2006;116(2):357-368.
18. Stein JH, Osgood RW, Barnes JL, Reineck HJ, Pinckard RN, McManus LM. The role of complement in the pathogenesis of postischemic acute renal failure. Miner Electrolyte Metab. 1985;11(4):256-261.
19. Park P, et al. Inhibiting the complement system does not reduce injury in renal ischemia reperfusion. J Am Soc Nephrol. 2001;12(7):1383-1390.
20. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170(3):1517-1523.
21. De Vries B, Matthijsen RA, Wolfs TG, Van Bijnen AA, Heeringa P, Buurman WA. Inhibition of complement factor C5 protects against renal ischemia-reperfusion injury: inhibition of late apoptosis and inf lammation. Transplantation. 2003;75(3):375-382.
22. Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol. 2004;172(6):3869-3875.
23. Renner B, et al. Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int. 2011;80(2):165-173.
24. Renner B, et al. The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol. 2010;185(5):3086-3094.
25. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006;20(2):217-226.
26. Peng Q, et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23(9):1474-1485.
27. Thurman JM. Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol. 2007;123(1):7-13.
28. de Vries DK, et al. Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation. Transplantation. 2013;95(6):816-820.
29. Naesens M, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol. 2009;20(8):1839-1851.
30. van Werkhoven MB, et al. Complement mediated renal inflammation induced by donor brain death: role of renal C5a-C5aR interaction. Am J Transplant. 2013;13(4):875-882.
31. Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat Rev Immunol. 2012;12(6):431-442.
32. Patel H, Smith RA, Sacks SH, Zhou W. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol. 2006;17(4):1102-1111.
33. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8(6):582-587.
34. Heeger PS, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med. 2005;201(10):1523-1530.
35. Strainic MG, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity. 2008;28(3):425-435.
36. Lalli PN, Strainic MG, Lin F, Medof ME, Heeger PS. Decay accelerating factor can control T cell differentiation into IFN-γ-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol. 2007;179(9):5793-5802.
37. Li K, et al. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. Blood. 2008;112(13):5084-5094.
38. Peng Q, et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol. 2009;183(10):6058-6068.
39. Pavlov V, et al. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol. 2008;181(7):4580-4589.
40. Esposito A, et al. Decay accelerating factor is essential for successful corneal engraftment. Am J Transplant. 2010;10(3):527-534.
41. + but not CD8+ cells are essential for allorejection. J Exp Med. 1996;184(5):2013-2018.
42. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393(6684):474-478.
43. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393(6684):480-483.
44. Vieyra M, et al. Complement regulates CD4 T-cell help to CD8 T cells required for murine allograft rejection. Am J Pathol. 2011;179(2):766-774.
45. Raedler H, Yang M, Lalli PN, Medof ME, Heeger PS. Primed CD8 (+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation. Am J Transplant. 2009;9(8):1784-1795.
46. Jane-Wit D, et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells. Circulation. 2013;128(23):2504-2516.
47. Gueler F, et al. Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol. 2008;19(12):2302-2312.
48. Raedler H, et al. Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice. Am J Transplant. 2011;11(7):1397-1406.
49. Cravedi P, Leventhal J, Lakhani P, Ward SC, Donovan MJ, Heeger PS. Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am J Transplant. 2013;13(10):2530-2539.
50. Li K, et al. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology. 2012;217(1):65-73.
51. Werfel T, et al. Activated human T lymphocytes express a functional C3a receptor. J Immunol. 2000;165(11):6599-6605.
52. Nataf S, Davoust N, Ames RS, Barnum SR. Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol. 1999;162(7):4018-4023.
53. Nataf S, Levison SW, Barnum SR. Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res. 2001;894(2):321-326.
54. Li K, et al. Expression of complement components, receptors and regulators by human dendritic cells. Mol Immunol. 2011;48(9-10):1121-1127.
55. Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS. Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation. 2008;86(9):1319-1321.
56. Roncarolo MG, Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007;7(8):585-598.
57. Burrell BE, Nakayama Y, Xu J, Brinkman CC, Bromberg JS. Regulatory T cell induction, migration, and function in transplantation. J Immunol. 2012;189(10):4705-4711.
58. Strainic MG, Shevach EM, An F, Lin F, Medof ME. Absence of signaling into CD4 (+) cells via C3aR and C5aR enables autoinductive TGF-beta1 signaling and induction of Foxp3 (+) regulatory T cells. Nat Immunol. 2013;14(2):162-171.
59. van der Touw W, Cravedi P, Kwan WH, Paz-Artal E, Merad M, Heeger PS. Cutting edge: Receptors for C3a and C5a modulate stability of alloantigenreactive induced regulatory T cells. J Immunol. 2013;190(12):5921- 5925.
60. Kwan WH, van der Touw W, Paz-Artal E, Li MO, Heeger PS. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med. 2013;210(2):257-268.
61. van der Touw W, Paolo C, Wing K, Heeger PS. Blocking C3a/C5a-receptor signaling promotes induction and stability of murine and human alloreactive regulatory T cells. In: American Transplant Congress Meeting; May 18-22, 2013; Seattle, Washington, USA. Abstract 162.
62. Cardone J, et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol. 2010;11(9):862-871.
63. Lachmann N, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87(10):1505-1513.
64. Pepys MB. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med. 1974;140(1):126-145.
65. Fang Y, Xu C, Fu YX, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol. 1998;160(11):5273-5279.
66. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271(5247):348-350.
67. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol. 2013;13(6):412-426.
68. Marsh JE, Farmer CK, Jurcevic S, Wang Y, Carroll MC, Sacks SH. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation. 2001;72(7):1310-1318.
69. Baldwin WM, Baldwin WM 3rd, Valujskikh A, Fairchild RL. Antibody-mediated rejection: emergence of animal models to answer clinical questions. Am J Transplant. 2010;10(5):1135-1142.
70. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280(14):735-739.
71. Wang H, et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol. 2007;179(7):4451- 4463.
72. Stegall MD, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405-2413.
73. Locke JE, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9(1):231-235.
74. Freitas MC, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95(9):1113-1119.
75. Crespo M, et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol. 2013;29(1-4):28-33.
76. Picascia A, Infante T, Napoli C. Luminex and antibody detection in kidney transplantation. Clin Exp Nephrol. 2012;16(3):373-381.
77. Loupy A, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369(13):1215-1226.
78. Collins AB, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol. 1999;10(10):2208-2214.
79. Hayde N, et al. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol. 2013;8(12):2141-2148.
80. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378(9800):1428-1437.
81. Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl. 2006:1-27.
82. Cravedi P, Perico N, Remuzzi G. Non-immune interventions to protect kidney allografts in the long term. Kidney Int. 2010; (119): S71-S75.
83. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012;23(12):1917-1928.
84. Sheerin NS, et al. Synthesis of complement protein C3 in the kidney is an important mediator of local tissue injury. FASEB J. 2008;22(4):1065-1072.
85. Tang Z, Lu B, Hatch E, Sacks SH, Sheerin NS. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol. 2009;20(3):593-603.
86. Zhou X, et al. Complement 3 activates the renal renin-angiotensin system by induction of epithelial-to-mesenchymal transition of the nephrotubulus in mice. Am J Physiol Renal Physiol. 2013;305(7):F957-F967.
87. Halimi JM. Low-grade proteinuria and microalbuminuria in renal transplantation. Transplantation. 2013;96(2):121-130.
88. Jeong JC, et al. Association of complement 5 genetic polymorphism with renal allograft outcomes in Korea. Nephrol Dial Transplant. 2011;26(10):3378- 3385.
89. Brown KM, et al. Influence of donor C3 allotype on late renal-transplantation outcome. N Engl J Med. 2006;354(19):2014-2023.
90. Varagunam M, Yaqoob MM, Dohler B, Opelz G. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med. 2009;360(9):874-880.
91. Nakorchevsky A, et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J Am Soc Nephrol. 2010;21(2):362-373.
92. Banz Y, Rieben R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med. 2012;44(3):205-217.
93. Chen G, Chen S, Chen X. Role of complement and perspectives for intervention in transplantation. Immunobiology. 2013;218(5):817-827.